

National Lung Cancer Roundtable Summit

Optimizing Lung Cancer Biomarkers in Practice

September 22-23, 2020

Day 1: Tuesday, September 22, 2020

10:00am–11:00am ET

NLCRT Biomarker Summit Overview

As numerous NLCRT member organizations are embarking on initiatives to increase biomarker testing for non-small cell lung cancer (NSCLC), we believe it is time for a collective mission-oriented approach to bring these organizations together to bridge current gaps in awareness, testing, and knowledge of best practices and state-of-the-art treatment for all eligible patients with NSCLC. The NLCRT aims to align on strategies to optimize patients' and physicians' awareness of biomarker testing to increase uptake and ensure patients receive the most effective treatment.

The goals of the meeting are to share clinical experiences related to biomarker testing and develop strategies that NLCRT member organizations can embrace to optimize use of lung cancer biomarkers in practice.

10:00am–10:04am ET

Virtual Stage-Setting and Summit Logistics

Ryan Soisson

Facilitator

Soisson & Associates

10:04am–10:09am ET

Welcome

Ella Kazerooni, MD, MS, FACR

Chair, National Lung Cancer Roundtable

Professor of Radiology & Internal Medicine

University of Michigan

10:09am–10:17am ET

Overview and Objectives of the Biomarker Summit

M. Patricia Rivera, MD, ATSF, FCCP

Professor of Medicine, Division of Pulmonary and Critical Care Medicine

University of North Carolina at Chapel Hill

10:17am–10:27am ET

BREAKOUT SESSIONS: Participant Introductions
Participants will break into small groups for introductions.

10:27am–11:00am ET

The Big Goal: The Ideal State of Biomarker Testing

*Access to High Quality Biomarker Testing for All Eligible Patients with
Non-Small Cell Lung Cancer: No Patient Left Behind*

Participants will discuss the Big Goal for the Biomarker Summit.
What would the ideal state of biomarker testing for NSCLC look like?

10:27am–10:37am ET

Bruce Johnson, MD, FASCO

Chief Clinical Research Officer

Dana-Farber Cancer Institute



10:37am–10:47am ET

BREAKOUT SESSIONS: Participant Thoughts about the Big Goal

Access to High Quality Biomarker Testing for All Eligible Patients with Non-Small Cell Lung Cancer: No Patient Left Behind

Participants will break into small groups to discuss the ideal state of biomarker testing for NSCLC.

10:47am–11:00am ET

Patient Advocate Experiences

Gina Hollenbeck, RN, BSN

President
ALK Positive

Janet Freeman-Daily, ENG, MS

Co-Founder
ROS1ders

11:00am–11:10am ET

Break

11:10am–11:55am ET

The Current State of Biomarker Testing for All Eligible Patients with NSCLC

Participants will explore the barriers present in the receipt of biomarker testing through the lens of clinical stakeholder groups.

11:10am–11:12am ET

Confessional Panel Introductions and Breakout Sessions Process

M. Patricia Rivera, MD, ATSF, FCCP

Professor of Medicine, Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Ryan Soisson

Facilitator
Soisson & Associates

Professional Confessional Panel

Representatives from various stakeholder groups share their own contributions to barriers to biomarker testing for all eligible patients with NSCLC.

11:12am–11:18am ET

Primary Care

Richard Wender, MD

Chair, Department of Family Medicine and Community Health
Penn Medicine

11:18am–11:24am ET

Proceduralists

Farhood Farjah, MD, MPH, FACS

Associate Professor of Surgery
University of Washington

11:24am–11:30am ET

Oncologists

Edward Kim, MD, FASCO

Chair of the Department of Solid Tumor Oncology
Levine Cancer Institute

11:30am–11:36am ET

Pathologists

Maureen Zakowski, MD

Professor of Pathology
Mt. Sinai School of Medicine

11:36am–11:42am ET

Payers

Bryan Loy, MD, MBA

Corporate Medical Director
Humana



11:42am–11:55am ET

BREAKOUT SESSIONS: Panel Discussion

Participants will break into small groups to discuss their thoughts about the confessional panel.

11:55am–12:00pm ET

Confessional Panel Summary Remarks and Next Steps

M. Patricia Rivera, MD, ATSF, FCCP

Professor of Medicine, Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Ryan Soisson

Facilitator
Soisson & Associates

12:00pm–2:00pm ET

Break

2:00pm–3:20pm ET

Deep Dive: Barriers to Biomarker Testing for All Eligible Patients with NSCLC

Participants will explore in detail the barriers present in the receipt of biomarker testing for all eligible patients with NSCLC.

2:00pm–2:10pm ET

Welcome Back and Barrier Deep Dive Panel Introductions

Ignacio Wistuba, MD

Division Head *ad interim*, Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center

Introducing the Process for Further Exploration of Barriers and Poll Questions

Ryan Soisson

Facilitator
Soisson & Associates

Deep Dive: Barriers to Optimizing Use of NSCLC Biomarkers

An analysis of the top barriers to biomarker testing is conducted and understood by all participants. Speakers pose a poll question to kick off their presentations.

2:10pm–2:20pm ET

Knowledge Gaps Regarding the Need for Testing & Communication

Nikki Martin

Director of Precision Medicine Initiatives
LUNgevity Foundation

2:20pm–2:30pm ET

Procurement of Adequate Tissue for Sampling

Gerard Silvestri, MD, MS, FCCP

Hillenbrand Professor of Thoracic Oncology
Medical University of South Carolina

2:30pm–2:40pm ET

Choice of Assay & Design and Turnaround Time

Lynette Sholl, MD, FCAP

Chief of Thoracic Pathology
Brigham and Women's Hospital



2:40pm–2:50pm ET

BREAKOUT SESSIONS: Barriers Discussion

KNOWLEDGE GAPS, PROCUREMENT OF ADEQUATE TISSUE, AND CHOICE OF ASSAY & DESIGN AND TURNAROUND TIME

Participants will break into small groups to discuss their thoughts about the presentations as well as the poll results.

2:50pm–3:00pm ET

Accurate Interpretation of Results

Raymond Osarogiagbon, MBBS, FACP

Director of the Multidisciplinary Thoracic Oncology Program
Baptist Cancer Center, Memphis

3:00pm–3:10pm ET

Reimbursement, Cost & Coverage

Jennifer Malin, MD, PhD

Senior Medical Director of Oncology and Genetics
UnitedHealth Group

3:10pm–3:20pm ET

BREAKOUT SESSIONS: Barriers Discussion

ACCURATE INTERPRETATION OF RESULTS AND REIMBURSEMENT, COST & COVERAGE

Participants will break into small groups to discuss their thoughts about the presentations as well as the poll results.

3:20pm–3:25pm ET

Barrier Deep Dive Panel Summary Remarks

Ignacio Wistuba, MD

Division Head *ad interim*, Division of Pathology/Lab Medicine
The University of Texas MD Anderson Cancer Center

3:25pm–3:35pm ET

Break

3:35pm–4:25pm ET

Industry, Payer, and Advocacy Panel

Representatives from Industry, Payer, and Advocacy organizations will discuss the challenges they regard as most important to ensure that biomarker testing for all eligible patients with NSCLC becomes routine, efficient, and high quality, and ways in which their organizations can contribute to a national collective initiative to advance biomarker testing and ensure patients receive state-of-the-art care.

Robert Smith, PhD (Moderator)

Principal Investigator, NLCRT
Senior Vice President, Cancer Screening
American Cancer Society

Jennifer Norton

Vice President, US Value, Access and Pricing
Amgen

Katy Miller

US Franchise Head, EGFR
AstraZeneca

Casey O'Neill

Principal, Oncology Strategy
Genentech



Bryan Loy, MD, MBA
Corporate Medical Director
Humana

Jill Feldman
Co-Founder
EGFR Resisters

Upal Basu Roy, PhD, MPH
Vice President of Research
LUNGeVity Foundation

4:25pm–4:30pm ET

Closing Remarks and Discussion of Working Breakout Session Prep for Day 2

Ryan Soisson
Facilitator
Soisson & Associates

Day 2: Wednesday, September 23, 2020

10:00am–10:15am ET

Welcome and Highlights from Day 1 of the NLCRT Biomarker Summit

Bruce Johnson, MD, FASCO
Chief Clinical Research Officer
Dana-Farber Cancer Institute

Instructions for Working Breakout Sessions

Ryan Soisson
Facilitator
Soisson & Associates

10:15am–11:30am ET

Strategic Framework Exploration to Overcome Barriers to Optimizing Use of Biomarkers for All Eligible Patients with NSCLC

Meeting participants have signed up for/are assigned to a specific barrier breakout group. There will be 10 breakout groups – 5 barriers with 2 groups discussing each barrier. Each group will propose and prioritize the top 3 strategies to overcome the barriers to biomarker testing for all eligible patients with NSCLC.

Knowledge Gaps Regarding the Need for Testing & Communication

Farhood Farjah, MD, MPH, FACS
Associate Professor of Surgery
University of Washington

Robert Suh, MD
Interventional Radiologist
UCLA Health

Procurement of Adequate Tissue for Sampling

M. Patricia Rivera, MD, ATSF, FCCP
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of North Carolina at Chapel Hill

Gerard Silvestri, MD, MS, FCCP
Hillenbrand Professor of Thoracic Oncology
Medical University of South Carolina



Choice of Assay & Design and Turnaround Time

Ignacio Wistuba, MD
Division Head *ad interim*
Division of Pathology/Lab Medicine
The University of Texas
MD Anderson Cancer Center

John Longshore, PhD, FACMG
Director of Molecular Pathology
Carolinas Pathology Group
Carolinas HealthCare System

Accurate Interpretation of Results

Bruce Johnson, MD, FASCO
Chief Clinical Research Officer
Dana-Farber Cancer Institute

Edward Kim, MD, FASCO
Chair of the Department of Solid Tumor Oncology
Levine Cancer Institute

Reimbursement, Cost & Coverage

Dara Aisner, MD, PhD, FCAP
Associate Professor, Pathology
University of Colorado

Mark Fleury, PhD
Principal, Policy Development
Emerging Science
ACS CAN

BREAKOUT SESSIONS: Strategic Framework Exploration

Participants will break into small groups to propose and prioritize strategies to overcome barriers to NSCLC biomarker testing.

11:30am–11:45pm ET

Break

11:45am–12:20pm ET

Strategy Review: Breakout Group Leads Present Key Messages to the Summit Participants

Ryan Soisson

Facilitator

Soisson & Associates

12:20pm–12:30pm ET

Summit Closing Remarks and Next Steps

M. Patricia Rivera, MD, ATSF, FCCP

Professor of Medicine, Division of Pulmonary and Critical Care Medicine

University of North Carolina at Chapel Hill



Thank you
National Lung Cancer Roundtable
National Sponsors

Amgen
AstraZeneca
Bristol-Myers Squibb
Genentech
Lilly Oncology



@NLCRTNews
#NLCRTBiomarkerSummit

